Biotech RadarJobs updated

COMPANY

Paratek Pharmaceuticals

HQ: Boston, MA source · paratekpharma.com ↗ · Mid-Atlantic

Status: Acquired, now part of Gurnet Point Capital and Novo Holdings · How status works

FDA-approved therapeutic company Clinical Phase 3

31 open jobs · last seen Oct 23, 2026 · 28 sources

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Bacterial Infections Skin Structures and Soft Tissue Infections Community-acquired Pneumonia Bacterial Pneumonia Nontuberculous Mycobacterium Infections Mycobacterium Abscessus Infection Nontuberculous Mycobacterial Lung Disease Nontuberculous Mycobacterial Pulmonary Infection Infectious Skin Diseases Infectious Skin Disease Bacterial Skin Disease Acute Pyelonephritis Uncomplicated Urinary Tract Infection Cystitis Community-Acquired Infections PTK 0796 Omadacycline

31Open jobs12Trials (company is sponsor)2FDA records (2 yrs)13NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
Specialty Sales Representative (Buffalo, NY)Buffalo, NYOct 19, 2026Oct 20, 2026
Specialty Sales Representative (Altoona, PA)Altoona, PAOct 14, 2026Oct 15, 2026
Regional Business Director - Bone Health (Northeast)Field-based (territory not stated)Oct 6, 2026Oct 9, 2026
Key Account Manager (Charlotte, Washington DC, Raleigh/Durham)Field-based (territory not stated)Oct 5, 2026Oct 9, 2026
Key Account Manager (Chicago, Kansas City, Indianapolis)Field-based (territory not stated)Oct 5, 2026Oct 9, 2026

See all 31 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (31 open jobs at last check). source ↗
  2. FDA FDA New indication / efficacy supplement: NUZYRA (omadacycline tosylate) — NDA209816/18, May 13, 2026. Applicant at approval: Paratek Pharmaceuticals, Inc. source ↗
  3. FDA FDA New indication / efficacy supplement: NUZYRA (omadacycline tosylate) — NDA209817/18, May 13, 2026. Applicant at approval: Paratek Pharmaceuticals, Inc. source ↗
  4. Trial start Phase 1: Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections source ↗
  5. Trial start Phase 2: Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) source ↗
  6. Trial start Phase 3: Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia source ↗
  7. Trial start Phase 1: Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia source ↗
  8. Trial start Phase 2: IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis source ↗
  9. Trial start Phase 2: Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis source ↗
  10. Trial start Phase 3: Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI source ↗
  11. Trial start Phase 3: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) source ↗
  12. Trial start Phase 3: Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23) source ↗
  13. Trial start 3: Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) source ↗
  14. Trial start Phase 3: Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) source ↗
  15. Trial start Phase 2: Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) source ↗

Open jobs 31

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Specialty Sales Representative (Buffalo, NY)Field-based (territory not stated)Oct 19, 2026Oct 20, 2026Not stated
Specialty Sales Representative (Altoona, PA)Field-based (territory not stated)Oct 14, 2026Oct 15, 2026Mid
Regional Business Director - Bone Health (Northeast)Field-based (territory not stated)Oct 6, 2026Oct 9, 2026Senior
Key Account Manager (Charlotte, Washington DC, Raleigh/Durham)Field-based (territory not stated)Oct 5, 2026Oct 9, 2026Mid
Key Account Manager (Chicago, Kansas City, Indianapolis)Field-based (territory not stated)Oct 5, 2026Oct 9, 2026Mid
Key Account Manager (Los Angeles, San Francisco, Phoenix)Field-based (territory not stated)Oct 5, 2026Oct 9, 2026Mid
Specialty Sales Representative (Naperville, IL)Field-based (territory not stated)Oct 2, 2026Oct 9, 2026Mid
Specialty Sales Representative (Fort Myers, FL)Field-based (territory not stated)Oct 2, 2026Oct 9, 2026Mid
Specialty Sales Representative (Minneapolis, MN)Field-based (territory not stated)Oct 2, 2026Oct 9, 2026Mid
Specialty Sales Representative (Green Bay, WI)Field-based (territory not stated)Sep 30, 2026Oct 9, 2026Mid
Territory Manager - TYMLOS (Boise, ID)Field-based (territory not stated)Sep 23, 2026Oct 9, 2026Mid
Regional Business Director (Chesapeake)Field-based (territory not stated)Sep 22, 2026Oct 9, 2026Senior
Hospital Sales Representative (Cincinnati, OH)Field-based (territory not stated)Sep 22, 2026Oct 9, 2026Mid
Specialty Sales Representative (Sarasota, FL)Field-based (territory not stated)Sep 22, 2026Oct 9, 2026Mid
Associate Director, Human Resources (Commercial Business)King Of Prussia, Pennsylvania, United StatesSep 21, 2026Oct 9, 2026Senior
Specialty Sales Representative (Joliet/Champaign, IL)Field-based (territory not stated)Sep 18, 2026Oct 9, 2026Mid
Specialty Sales Representative (Pontiac, MI)Field-based (territory not stated)Sep 16, 2026Oct 9, 2026Mid
Hospital Sales Representative (Austin, TX)Field-based (territory not stated)Sep 16, 2026Oct 9, 2026Mid
Hospital Sales Representative (Northern NJ)Field-based (territory not stated)Sep 16, 2026Oct 9, 2026Mid
Specialty Sales Representative (Orlando North, FL)Field-based (territory not stated)Sep 15, 2026Oct 9, 2026Mid
Specialty Sales Representative (Indianapolis South, IN)Field-based (territory not stated)Sep 15, 2026Oct 9, 2026Mid
Specialty Sales Representative (Gainesville, FL)Field-based (territory not stated)Sep 15, 2026Oct 9, 2026Mid
Specialty Sales Representative (Erie, PA)Field-based (territory not stated)Sep 15, 2026Oct 9, 2026Mid
Specialty Sales Representative (Nashville South)Field-based (territory not stated)Sep 14, 2026Oct 9, 2026Mid
Specialty Sales Representative (Tallahassee, FL)Field-based (territory not stated)Sep 14, 2026Oct 9, 2026Mid
Territory Manager - TYMLOS (Roanoke)Field-based (territory not stated)Sep 14, 2026Oct 9, 2026Mid
Territory Manager - TYMLOS (Des Moines, IA)Field-based (territory not stated)Sep 14, 2026Oct 9, 2026Mid
Regional Business Director - Bone Health (Plains)Field-based (territory not stated)Sep 11, 2026Oct 9, 2026Senior
Director, Quality (External Manufacturing)King Of Prussia, Pennsylvania, United StatesAug 18, 2026Oct 9, 2026Senior
Senior Manager, Human Resources (Commercial Business)King Of Prussia, Pennsylvania, United StatesJul 1, 2026Oct 9, 2026Senior
Regional Business Director (Western Tri-State: Pittsburgh, Allentown, Reading)Field-based (territory not stated)Jun 23, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT05217537Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial InfectionsPhase 1CompletedApr 6, 2022Feb 27, 2025 (actual)
NCT04922554Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)Phase 2CompletedOct 15, 2021Jun 17, 2024 (actual)
NCT04779242Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial PneumoniaPhase 3CompletedFeb 25, 2021Mar 27, 2024 (actual)
NCT04160260Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial PneumoniaPhase 1CompletedNov 28, 2019Mar 23, 2020 (actual)
NCT00865280Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Phase 3TerminatedApr 4, 2009Apr 15, 2010 (actual)
NCT03716024Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Phase 2CompletedJul 18, 2007Jan 7, 2008 (actual)
NCT03757234IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute PyelonephritisPhase 2CompletedNov 19, 2018Jun 26, 2019 (actual)
NCT03425396Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of CystitisPhase 2CompletedJan 4, 2018May 15, 2019 (actual)
NCT02378480Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)Phase 3Completed2015-062016-04 (actual)
NCT02531438Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)Phase 3Completed2015-11Feb 5, 2017 (actual)
NCT02877927Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSIPhase 3Completed2016-08May 26, 2017 (actual)
NCT00876850Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)3Withdrawn2009-072010-07 (estimated)

FDA records (last 2 years)

NIH awards 13

Annual award amounts. Total $10.7M.

Connect

See your connections at Paratek Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback